expanding the right to try act to include certain qualifying severe illness and permitting certain regenerative stem cell therapies under the act.

Summary

The bill broadens the state’s Right‑to‑Try act so patients with a qualifying severe, chronic and debilitating illness can access unapproved drugs, biologics, devices, or individualized treatments. It also creates a regulatory framework for regenerative stem‑cell therapies, including consent and advertising rules, while banning stem cells derived from fetal or embryonic tissue after an abortion. The changes aim to give seriously ill patients more treatment options while setting ethical limits.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share